344 completed, 57 unknown, 33 recruiting, 19 active not recruiting. 103 Phase 1, 101 Phase 2, 83 Phase 3, 66 Not applicable, 37 Phase 4.
Follow Flavivirus Infections: new trials by email Literature Review of Flavivirus Infections trials Research Report on Flavivirus Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years. DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555), DENGUE: Dengue 1,2,3,4 (attenuated) vaccine, Chikungunya (CHIKV) live attenuated vaccine (VLA1555) - Dengue, Chikungunya | Phase 3 | Not yet recruiting | Butantan Institute | 900 | 2027-03-31 | 2026-07-16 |
| Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 100 µg (25 µg of each VLP) + ALFQ adjuvant - Randomised Clinical Trial, Double Blind | Phase 1 | Not yet recruiting | VLP Therapeutics | 42 | 2027-01-04 | 2026-09-21 |
| Investigating and Modelling the Natural History of Dengue in Hospitalised Patients to Improve Future Research Dengue | Not yet recruiting | Liverpool School of Tropical Medicine | 235 | 2026-11-01 | 2026-09-02 | |
| Therapeutics for Moderate and Severe Dengue Placebo, Dexamethasone, N-Acetylcysteine - Dengue, Severe Dengue | Phase 3 | Not yet recruiting | Oxford University Clinical Research Unit, Vietnam | 8800 | 2026-10-01 | 2026-04-21 |
| Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative) Emetine Hydrochloride 6mg, Placebo, Emetine Hydrochloride 12mg - Dengue | Phase 2 / Phase 3 | Recruiting | Johns Hopkins University | 600 | 2026-09-01 | 2026-10-13 |
| Baseline Assessment of Skin Resident Memory T Cells in Healthy Unvaccinated Participants Skin punch biopsy, Blood samples - Yellow Fever (Healthy Volunteers), Biopsy/Methods | Not applicable | Recruiting | Institute of Tropical Medicine, Belgium | 40 | 2026-08-10 | 2026-08-13 |
| Smart Analysis and Decision-Making for Emerging Infectious Diseases Multi-Agent Integrated Smart Toolkit for Emerging Infectious Diseases, Routine Practices - Emerging Infectious Diseases, COVID-19 | Not applicable | Enrolling by invitation | Peking University | 108 | 2026-08-10 | 2026-08-19 |
| Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection rDEN2delta30-7169 - Healthy Volunteers, Dengue | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 200 | 2026-08-07 | 2026-10-22 |
| Gut Leakage' in Dengue Dengue, Dengue Hemorrhagic Fever | Recruiting | University of Oxford | 190 | 2026-08-01 | 2026-08-06 | |
| Effects Of A Rehabilitation Protocol On Muscle Strength, Muscle Fatigue And Postural Control In Post-Dengue And Chikungunya Patients Exercise - Dengue, Chikungunya | Not applicable | Not yet recruiting | Universidade do Estado do Pará | 54 | 2026-07-01 | 2026-05-26 |
| Adaptive Dengue Antiviral Platform Trial Molnupiravir 400 mg, VIS513 (a monoclonal antibody), Remdesivir 100mg - Dengue, Antiviral Drugs | Phase 2 | Recruiting | Oxford University Clinical Research Unit, Vietnam | 500 | 2026-04-20 | 2026-09-28 |
| A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2) CP-COV03, Placebo - Dengue | Phase 2 / Phase 3 | Recruiting | Hyundai Bioscience Co., Ltd. | 210 | 2026-04-09 | 2026-07-10 |
| Using Digital Technology for the Prevention of Aedes-Borne Diseases in Colombian Communities Full intervention, Partial intervention - Dengue, Zika | Not applicable | Completed | University of Freiburg | 900 | 2026-03-26 | 2026-04-08 |
| Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2) Resomelagon, Placebo, Standard Treatment - Dengue Fever | Phase 2 | Recruiting | Federal University of Minas Gerais | 120 | 2026-03-20 | 2026-09-15 |
| Demographic Characteristics of TAK-003 Dengue Vaccine Recipients in Vietnam Dengue | Active not recruiting | Tam Anh Research Institute | 800000 | 2026-03-16 | 2026-04-13 | |
| A Controlled Human Infection Model of Dengue GMP-produced rDEN3delta30 virus - Dengue | Not applicable | Active not recruiting | Tan Tock Seng Hospital | 5 | 2026-03-05 | 2026-10-16 |
| Butantan-DV Vaccine in Elderly Populations (DEN-04-IB) Dengue 1,2,3,4 (attenuated) vaccine - Dengue | Phase 3 | Recruiting | Butantan Institute | 997 | 2026-03-03 | 2026-07-16 |
| Bridging Economics and Public Trust: A Study of Dengue Vaccine Cost-effectiveness and Acceptance in Thais Visiting Hospital Objective 1- economic evaluation of Thai children with dengue vaccine - Dengue Fever | Active not recruiting | Mahidol University | 350 | 2026-02-02 | 2026-08-17 | |
| A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years) TDV, Placebo - Dengue Fever | Phase 3 | Active not recruiting | Takeda | 800 | 2026-01-20 | 2026-09-22 |
| First-in-Human Study Testing a New Antibody Treatment for Tick-Borne Encephalitis in Healthy Volunteers. Human monoclonal antibody TBE025, intravenous infusion - The Tick-borne Encephalitis Virus (TBEV) | Phase 1 | Not yet recruiting | Giuseppe Pantaleo | 18 | 2026-01-01 | 2026-01-29 |
Showing 20 of 501. Sign in to see all of them.
Dengue (275) · Zika Virus Infection (77) · Encephalitis, Japanese (72) · Severe Dengue (65) · Encephalitis, Tick-Borne (50) · Yellow Fever (44) · Chikungunya Fever (34) · Virus Diseases (18) · Encephalitis (12) · West Nile Fever (12) · Arbovirus Infections (11) · Malaria (11) · Fever (9) · Measles (8)
Flaviviridae Infections (498) · Infections (498) · RNA Virus Infections (497) · Vector Borne Diseases (495) · Arbovirus Infections (490) · Virus Diseases (483) · Mosquito-Borne Diseases (450) · Hemorrhagic Fevers, Viral (315) · Nervous System Diseases (144) · Central Nervous System Diseases (135) · Central Nervous System Infections (135) · Neuroinflammatory Diseases (135) · Brain Diseases (134) · Central Nervous System Viral Diseases (133)
Vaccines (21) · Yellow Fever Vaccine (18) · Dengue Vaccines (14) · Blood Specimen Collection (13) · Sodium Chloride (12) · Japanese Encephalitis Vaccines (11) · Aluminum Hydroxide (5) · Data Collection (5) · Measles-Mumps-Rubella Vaccine (5) · Surveys and Questionnaires (5) · Hepatitis A Vaccines (4) · Saline Solution (4) · Urination (4) · AT-752 (3) · Biological Products (3)
National Institute of Allergy and Infectious Diseases (NIAID) (52) · Sanofi Pasteur, a Sanofi Company (49) · Pfizer (19) · Takeda (18) · Valneva Austria GmbH (17) · Sanofi (15) · U.S. Army Medical Research and Development Command (15) · Mahidol University (8) · PATH (7) · University Medical Centre Ljubljana (7) · GlaxoSmithKline (6) · Institute of Tropical Medicine, Belgium (6) · Singapore General Hospital (6) · Butantan Institute (5) · Institut Pasteur (5)
United States (115) · Brazil (42) · Thailand (41) · Colombia (29) · Mexico (24) · Germany (22) · Singapore (21) · Vietnam (21) · Malaysia (20) · Philippines (20) · Puerto Rico (20) · Austria (19) · France (15) · Australia (12) · Bangladesh (12)
Anna Durbin, MD (30) · Beth Kirkpatrick, MD (4) · Kristen Pierce, MD (4) · Astrid Kaltenboeck, Ph.D. (3) · Myrielle Dupont-Rouzeyrol, PhD (3) · Ryszard Konior, MD (3) · Stephen J Thomas, MD (3)
PMID 40099800, PMID 42253092, PMID 26214039, PMID 29897841, PMID 33822015, PMID 26383952, PMID 29217375, PMID 31878895, PMID 39116904, PMID 20934459, PMID 21592984, PMID 23563266, PMID 25801652, PMID 26424605, PMID 26458804, PMID 27007959, PMID 27418050, PMID 27459266, PMID 28545923, PMID 28871961, PMID 29300876, PMID 31984244, PMID 32220283, PMID 32394880, PMID 32572470, PMID 32932330, PMID 33212068, PMID 33422034, PMID 34003796, PMID 34107180, PMID 34219653, PMID 35659904, PMID 36057771, PMID 36682364, PMID 37254133, PMID 37971871, PMID 38294972, PMID 39308445, PMID 39356094, PMID 42480195, PMID 10632996, PMID 15272410, PMID 15499438, PMID 15577938, PMID 15714427, PMID 15741556, PMID 16269927, PMID 16494976, PMID 16603571, PMID 17316925
2014 (6), 2019 (4), 2009 (2), 2018 (2), 2023 (2), U19AI057266 (2), 2008 (1), 2016 (1), 272201300017C-18-0-1 (1), R01HD102445 (1), R21AI139777 (1), R21HD095420 (1), R21HD096369 (1), U01AI141981 (1), U01AI148069 (1)